BioNTech, the German biotech that partnered with Pfizer to develop the first COVID-19 vaccine to earn the FDA’s emergency use authorization, is now using mRNA to tackle another disease: malaria. The ...

BioNTech aims to develop the first mRNA-based vaccine for Malaria prevention with the initiation of a clinical trial by end of 2022 BioNTech is evaluating sustainable mRNA vaccine production ...

BERLIN (AP) — Pharmaceutical company BioNTech said Monday that it wants to use the mRNA technology behind its coronavirus vaccine to target malaria. The Germany-based company, which developed the ...

BioNTech SE (NASDAQ:BNTX) said on Tuesday, that the U.S. Food and Drug Administration informed of a clinical hold on the company's Investigational New Drug application and mid-stage trial evaluating ...

BioNTech aims to develop the first mRNA-based vaccine for Malaria prevention based on a novel multi-antigen vaccine approach First evaluated candidate BNT165b1 expresses certain parts of the ...

Expanding Africa’s capacity to produce mRNA vaccines has reached a new milestone with BioNTech’s opening of a facility in Kigali, Rwanda. This facility is designated for manufacturing vaccines for use ...

BioNTech SE announced the initiation of a first-in-human phase 1 study with BNT165b1, the first candidate from the company’s BNT165 programme, to develop a multi-antigen malaria vaccine candidate.

Investing.com – BioNTech (NASDAQ:BNTX) stock rose more than 3% Monday following the launch of the company’s ‘Project Malaria’ which aims to develop a vaccine to prevent malaria in Africa. The vaccine ...

The FDA placed a clinical hold on BioNTech’s Phase 1/2a trial for its investigational RNA-based malaria vaccine, BNT165e. BioNTech paused the study and is working with the FDA to address its requests ...

BioNTech is diversifying its portfolio beyond its COVID-19 vaccine, focusing on antibody-drug conjugates (ADCs) and novel vaccines. The company has acquired MediLink Therapeutics' ADC technology and ...